Changing Attitudes about Open Innovation at AstraZeneca

Turning colleagues from open innovation skeptics to advocates isn’t easy, but Scott Wilkins says it has steadily begun to happen over five years of hard work at AstraZeneca , the $25 billion British pharmaceutical firm. “There’s just a lot of groups we had to work with…